Four months after the FDA slapped a clinical hold on Beam Therapeutics’ phase 1 ready off-the-shelf CAR-T, the biotech is now free to proceed. The agency’s concerns about the therapy, dubbed BEAM-201, ...
Shares of Beam Therapeutics (NASDAQ:BEAM) reached a 52-week high on Tuesday after the gene-editing company swung to profits in Q4, exceeding Wall Street projections as its revenue jumped thanks to a ...
Beam TherapeuticsBEAM had its Relative Strength (RS) Rating upgraded from 79 to 84 Thursday. Please watch the video at Investors.com - What Are The Magnificent Seven Stocks? Risk Management In The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results